<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6222">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044264</url>
  </required_header>
  <id_info>
    <org_study_id>DAC-501-601-727998</org_study_id>
    <nct_id>NCT01044264</nct_id>
    <nct_alias>NCT00807638</nct_alias>
  </id_info>
  <brief_title>Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations</brief_title>
  <official_title>A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled Study Comparing Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations in the Treatment of Moderate to Severe Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perrigo Company</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, multiple-site, placebo-controlled, parallel-group clinical study
      conducted to evaluate the bioequivalence of two 1% Clindamycin/5% Benzoyl Peroxide Topical
      Gel formulations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction of Inflammatory Lesions</measure>
    <time_frame>Baseline and week 11</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint of the study was the mean percent reduction from baseline to week 11 in inflamed lesion count (papules and pustules).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">602</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1% Clindamycin/5% Benzoyl Peroxide Topical Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Test product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Clindamycin/5% Benzoyl Peroxide Topical Gel</intervention_name>
    <description>Topical Gel</description>
    <arm_group_label>1% Clindamycin/5% Benzoyl Peroxide Topical Gel</arm_group_label>
    <arm_group_label>DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel</arm_group_label>
    <other_name>DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy men or women, 12 years of age and older

          -  willing to participate and sign a copy of the informed consent form

          -  moderate to severe facial acne

        Exclusion Criteria:

          -  history of allergy or hypersensitivity to clindamycin or benzoyl peroxide

          -  pregnant or lactating women

          -  evidence of a clinically significant disorder

          -  receipt of any drugs as part of a research study within 30 days prior to study dosing

          -  use of systemic, topical or facial products which may interfere with study

          -  significant facial hair, tattoos, excessive facial scarring, active facial sunburn,
             or peeling due to sunburn
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 17, 2013</lastchanged_date>
  <firstreceived_date>January 4, 2010</firstreceived_date>
  <firstreceived_results_date>September 14, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>bioequivalency</keyword>
  <keyword>clindamycin</keyword>
  <keyword>benzoyl peroxide</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>FIRST PATIENT ENROLLED: 12/11/2007 LAST PATIENT COMPLETED: 9/18/2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1% Clindamycin/5% Benzoyl Peroxide Topical Gel</title>
          <description>Test product
1% Clindamycin/5% Benzoyl Peroxide Topical Gel : Topical Gel</description>
        </group>
        <group group_id="P2">
          <title>DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel</title>
          <description>Reference product
1% Clindamycin/5% Benzoyl Peroxide Topical Gel : Topical Gel</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo : Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="92"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1% Clindamycin/5% Benzoyl Peroxide Topical Gel</title>
          <description>Test product
1% Clindamycin/5% Benzoyl Peroxide Topical Gel : Topical Gel</description>
        </group>
        <group group_id="B2">
          <title>DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel</title>
          <description>Reference product
1% Clindamycin/5% Benzoyl Peroxide Topical Gel : Topical Gel</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo : Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="200"/>
                <measurement group_id="B2" value="202"/>
                <measurement group_id="B3" value="200"/>
                <measurement group_id="B4" value="602"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="117"/>
                <measurement group_id="B2" value="113"/>
                <measurement group_id="B3" value="113"/>
                <measurement group_id="B4" value="343"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="83"/>
                <measurement group_id="B2" value="89"/>
                <measurement group_id="B3" value="87"/>
                <measurement group_id="B4" value="259"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="19.2" spread="7.3"/>
                <measurement group_id="B2" value="19.5" spread="7.1"/>
                <measurement group_id="B3" value="20.1" spread="8.3"/>
                <measurement group_id="B4" value="19.6" spread="7.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="103"/>
                <measurement group_id="B2" value="101"/>
                <measurement group_id="B3" value="113"/>
                <measurement group_id="B4" value="317"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="97"/>
                <measurement group_id="B2" value="101"/>
                <measurement group_id="B3" value="87"/>
                <measurement group_id="B4" value="285"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="200"/>
                <measurement group_id="B2" value="202"/>
                <measurement group_id="B3" value="200"/>
                <measurement group_id="B4" value="602"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Inflammatory Lesions</title>
        <description>The primary endpoint of the study was the mean percent reduction from baseline to week 11 in inflamed lesion count (papules and pustules).</description>
        <time_frame>Baseline and week 11</time_frame>
        <safety_issue>No</safety_issue>
        <population>per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>1% Clindamycin/5% Benzoyl Peroxide Topical Gel</title>
            <description>Test product
1% Clindamycin/5% Benzoyl Peroxide Topical Gel : Topical Gel</description>
          </group>
          <group group_id="O2">
            <title>DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel</title>
            <description>Reference product
1% Clindamycin/5% Benzoyl Peroxide Topical Gel : Topical Gel</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo : Placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="110"/>
                  <measurement group_id="O2" value="108"/>
                  <measurement group_id="O3" value="185"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Reduction of Inflammatory Lesions</title>
            <description>The primary endpoint of the study was the mean percent reduction from baseline to week 11 in inflamed lesion count (papules and pustules).</description>
            <units>percentage reduction of lesions</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="64.39"/>
                  <measurement group_id="O2" value="63.10"/>
                  <measurement group_id="O3" value="49.89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>BE of the test to reference in the per protocol population</non_inferiority_desc>
            <param_type>Wilcoxon Rank Sum Test</param_type>
            <param_value>100</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.47</ci_lower_limit>
            <ci_upper_limit>113.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>11 week treatment period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1% Clindamycin/5% Benzoyl Peroxide Topical Gel</title>
          <description>Test product
1% Clindamycin/5% Benzoyl Peroxide Topical Gel : Topical Gel</description>
        </group>
        <group group_id="E2">
          <title>DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel</title>
          <description>Reference product
1% Clindamycin/5% Benzoyl Peroxide Topical Gel : Topical Gel</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo : Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="0"/>
                <counts group_id="E3" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Kidney Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Bipolar Conduct Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>application site dryness</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Application Site Burning</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager</name_or_title>
      <organization>Perrigo Company</organization>
      <phone>718-960-0119</phone>
      <email>jonathan.schwartz@perrigo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
